| |

Math Over Myth: Positive Technical Divergences in the Psychedelic Sector

Math over Myth
Math over Myth

Investing in the stock market is a fancy euphemism for gambling. But unlike traditional brick-and-mortar joints with slots, craps, and blackjack, the Crazy Capitalist Casino allows you to bet on the house – and the house always wins. How can the average retail investor adopt a healthy risk-and-reward mindset? Math Over Myth!

Math Over Myth removes romance and mythology from investing to focus strictly on price movements, mathematics, and technical analysis. Regardless of long term value and growth prospects in medicinal psychedelics, the public market space is still very young and volatile. While fundamentals aren’t entirely irrelevant, adopting a savvy gambler mentality requires a healthy dose of nihilism in this department.

Betting on emerging, disruptive, and speculative sectors of the marketplace doesn’t necessarily need to be a risky endeavor if you approach it with the right mindset, formulate a plan which allows you to remove the romance from the good time and not second-guess your strategy during bad times. Today we refocus on the actively managed AdvisorShares Psychedelic ETF PSIL.

Psychedelic Sector ETF

Spotlight previously covered AdvisorShares Psychedelic ETF (NYSEARCA: PSIL) in a primer for the sector’s exchange traded funds and their utility in amplifying gains while mitigating risk:

PSIL is the only one which is actively managed… This allows them to invest [large] sums into smaller companies they believe have greater opportunity [and] quickly rebalance their ETF in response to changing variables. PSIL is a pure-play psychedelic medicines ETF, with [all 28 constituents] being a psychedelic [stocks]. They have $5.9 million under management.

Actively managed PSIL confirmed a bottom of approximately $2.50/share, which first occurred in Q2 2022 (mid May), once during Q3. Since October began, PSIL pulled back from $3.25 with a downward trajectory, and on October 13th I predicted a retest of its support level @ $2.50/share.

After a successful retest and brief uptick, the bears successfully breached $2.50 last Wednesday and sustained it through last Friday’s close.

Spotting A Great Divergence in The Force

What are technical divergences? What do they mean? How do I spot them? It’s a great time to explore these questions using PSIL.

A divergence occurs when a lower indicator (below the price chart), such as the Relative Strength Index (RSI), forms a pattern opposite to the chart’s price action. PSIL’s daily chart is a real time example of a technical divergence. Its price made a lower low, $2.42 down from $2.50, while the RSI (first lower indicator) made a higher low. This is commonly referred to as a positive or bullish reversal signal.

See the daily chart below with thick, solid white lines demonstrating these technical divergences from PSIL’s price action in the RSI, Money Flow Index (MFI), and Moving Average Convergence Divergence (MACD) oscillators.

One technical divergence is a great sign, but three is a blaring bullhorn. Positive technical divergences signal supply side exhaustion. In other words, the bears are growing weary of selling.

The RSI divergence implies that the strength of the sell off is waning since late September. Divergences in the MFI signal money flowing back into PSIL during the sell off in early October. Similarly, the MACD highlights divergences in the daily chart’s moving averages. While no one single indicator is a panacea, this amalgamation tells a strong tale of trend reversal.

However, it doesn’t necessarily mean that PSIL snaps the downtrend and reverses course right away. For instance, PSIL can continue diverging and potentially drop to its next support level of $2.04/share.

Never try and catch a falling dagger unless you enjoy bleeding. Wait for confirmation, assess your risk tolerance, and deploy mitigation strategies accordingly.

Macro Tailwind Factors

Any emerging, speculative, growth sector like psychedelics is destined to be coupled to broad market action, but with increased volatility: higher highs and lower lows. When the markets start to move in a positive direction, investors feel comfortable jumping back into the warm water. This type of phenomenon should be a boon to PSIL and the psychedelic space.

Fortunately, charts like SPY and QQQ, S&P 500 and Nasdaq 100 ETFs, respectively, already popped last week after making their own positive divergences in weeks prior. Moreover, Biotech ETF XBI recently flipped old support into new resistance on its chart and made a double bottom to test and confirm its new support level through successful defenses by buyers. These are all important, strong signals of markets ready to reverse.

Conclusions

After over-hiking rates and scaring liquidity out of the game for about two months, perhaps the Federal Open Market Committee (FOMC) learned their lesson and won’t score the ultimate own goal by unnecessarily further tightening the money supply, thus squeezing a recovering economy with a growing labor force and long overdue wage growth into an unprovoked recession.

However, my experienced and educated guess is the FOMC will ultimately get the message and back off their aggressive tightening, rate-hiking hawkishness. After all, inflation is a global phenomenon currently catalyzed by supply chain disruptions still being felt by COVID and one of the largest energy producers invading the world’s bread basket. Naturally global food and energy prices are up.

But how is the United States fairing by contrast? It may shock you to learn that, relative to much of the world, America’s inflation rate is rather paltry by comparison.

All of these factors tell me markets have already bottomed out and will begin to consolidate as liquidity moves from the sidelines back into the casino.

This can only benefit PSIL and the psychedelic sector. With other company catalysts to come in Q4, as well Colorado’s ballot initiative, Senator Booker furthering conversations in the senate, and the DEA significantly increasing their 2023 quotas for the production of psychedelics like psilocyn, LSD, 5-MeO-DMT, and mescaline (DMT, MDA, MDMA, and psilocybin will remain at 2022 levels), all signs point to a better autumn for psychedelic stocks.

 

Craig D. Schlesinger is a professional gambler and market analyst with over twenty years experience predicting price movements and trend reversals in various economic sectors. Over the last two years, Craig established himself as a top trusted authority on psychedelic equities. Follow his technical analysis on Twitter: @mathovermyth.

Math Over Myth Primer | Math Over Myth Archive

Craig holds no positions in PSIL, SPY, QQQ, or XBI

*This article was written before markets opened on Monday October 23, 2022

Similar Posts

  • Mixing Psychedelics & Antidepressants: Is it Safe? | NEW Psilocybin Study

    As using psychedelics as medicines for mental health conditions has become more popular, it has been an open question of whether substances such as psilocybin (magic mushrooms) can safely be combined with anti-depressants such as SSRIs.
    Now, Compass Pathways (CMPS) has released a small study, which showed that it is in fact safe to combine the two drugs. This is the second such small study to come to this conclusion. Earlier this year, MindMed, (MNMD / MMED) had released data on a similar study, with similar results
    However, it is important to note that these are two very small studies, and that nothing has been definitively proven yet.
    Many argue that psychedelics like psilocybin should be a replacement for depression medications such as SSRIs, not another layer of medicine. While I am sympathetic to this view, we must ultimately follow the science.
    Compass Pathways will use the results of this trial to inform the design of their upcoming phase 3 trial testing whether psilocybin can treat treatment resistant depression.
    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy
    @Psychedelic Spotlight

    #psychedelics #antidepressants #psilocybin

  • Does Microdosing Mushrooms Work? ( Interview with Sena Maria)

    Hello Psychedelic Investors! The topic of today’s video is “Does microdosing mushrooms work?” We usually talk about investing in psychedelic stocks and companies inspired by microdosing psychedelics with the mission to cure depression, anxiety, adhd, etc. But we never really dove deep into the science of microdosing. Does Microdosing Magic Mushrooms really work? So before investing in companies like MindMed (MMED/MMEDF), Compass Pathways (CMPS), Numi, Field Trip Health (FTRP) or Atai Life Sciences, listening to someone who’s got a personal experience with psychedelics might not be such a bad idea.

    One of the reasons behind the interview with pro in the Microdosing psilocybin realm is that recent studies have shown that the benefits of microdosing can be attributed completely to placebo effects. That’s why I decided to have a talk with Sena Maria. Sena is passionate about working with the fungi realm to support our collective evolution. Coming from Google in Silicon Valley she took a big life pivot and has spent the last 5 years learning from the plants. After supporting hundreds of people in getting started with microdosing, she now shares what she’s learned on her YouTube channel The Medicine of Being Human and her instagram @sena__maria.

    So what do you guys think? Is Microdosing Psychedelics the Future of Medicine? Hopefully some of the new MMED or CMPS or any other psychedelic stocks investors got some value in this! What do you guys think?

    You can learn more about microdosing in her popular webinar Microdosing For Resilience at www.medicineofbeinghuman.com

    Timestamps:

    0:00 – Intro
    1:11 – What is Microdosing & How does it Work?
    2:55 – Microdosing Benefits
    7:28 – Why Microdosing? ( Regimen & Protocols)
    14:12 – Discussing microdosing & placebo effects
    19:21 – Personal Microdosing Experiences & Consistency
    24:09 – Microdosing Advice for Beginners

    #PsychedelicStocks #MindMed #MicrodosingPsilocybin

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.